Pharmacokinetics parameters in transplant cases.

<p>Pharmacokinetics parameters in transplant cases.</p

Frutcherman-Rheingold plot of multifactor dimensionality reduction analysis.

<p>Multifactor dimensionality reduction analysis revealed that CYP3A5*3 (X1) interacts strongly with ABCB1 1236 (X2) and ABCB1 2677 (X3) variants in influencing bioavailability of tacrolimus.</p

Impact of age, gender and BMI on the bioavailability of tacrolimus.

<p>ANN simulation illustrating (A) Age-dependent changes in bioavailability of tacrolimus in men and women; (B) Bioavailability of tacrolimus in men and women according to BMI.</p

Gene-gene interactions modulating the tacrolimus bioavailability.

<p>ANN simulations depicting gene-gene interactions in modulating tacrolimus bioavailability. (A) CYP3A5*3 -ABCB1 1236 C>T; (B) CYP3A5-ABCB1 2677 G>T/A; (C) CYP3A5-ABCB1 3435 C>T.</p

The input and output variables of the developed ANN model.

<p>The input and output variables of the developed ANN model.</p

Cross-validation of ANN model.

<p>Five fold-cross validation of ANN model showed good agreement between experimental vs predicted trough/dose ratio (r² = 0.94 to 0.96).</p

Logistic regression analysis showing the impact of demographic and genetic variables contributing to post transplant diabetes.

<p>Logistic regression analysis showing the impact of demographic and genetic variables contributing to post transplant diabetes.</p

Impact of CYP3A5 and ABCB1 genotypes on the bioavailability of tacrolimus.

<p>ANN simulations depicting genotype based association of tacrolimus bioavailability in (A) men; (B) women.</p

Primers used for genetic analysis.

<p>Primers used for genetic analysis.</p